Drugs / TORL-5-700
last change Mar 2026 re-read 3 minutes ago

TORL-5-700

Developed for
B-cell non-Hodgkin lymphoma
Investigated by
TORL Biotherapeutics, LLC

Trials 1

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07439653 Mar 2026 → Mar 2029 expected B-cell non-Hodgkin lymphoma TORL Biotherapeutics, LLC Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TORL-5-700 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07439653 ↗